The five-year packaging contract comes off the back of AstraZeneca’s $80m investment in new machinery at its Sydney plant in response to significant growth and demand for a respiratory medicine from the Chinese health care system.

Alex Commins, managing director, Colorpak says, “The re-signing of the contract is a great outcome and supports a mutually beneficial business partnership. We are excited to have once more extended our supply partnership with one of Australia’s blue chip pharmaceutical manufacturers.”

Commins says Colorpak has had a strong focus and commitment to the pharmaceutical sector for decades and the respective management teams have developed a true partnership that underpins sustainable growth for both businesses.

He says, “Colorpak has long believed that its modern facilities incorporating its equipment and systems are essentially the way we make our customers internationally competitive and this agreement underlines the importance of our approach. This is terrific news for our stakeholders and the broader Australian economy.”

Stuart Anderson, director of manufacturing and supply, AstraZeneca Australia says the investment in AstraZeneca Australia’s manufacturing operations represents the company’s long term ambition to become a centre of excellence for high-tech production as an export hub to Asia.

Anderson says, “Our partnership with Colorpak is an important relationship in delivering the 500 per cent growth of exports that we will experience to China by 2015.”

Comment below to have your say on this story.

If you have a news story or tip-off, get in touch at editorial@sprinter.com.au.  

Sign up to the Sprinter newsletter